Access Biotechnology is in line for an exit after the neuronal excitability disorder drug developer filed to float on the Nasdaq Global Market.
Eliem Therapeutics, a US-based developer of treatments for neuronal excitability disorders, has filed for an $80m initial public offering, presenting an opportunity to exit for conglomerate Access Industries.
Founded in 2019, Eliem is developing novel drug treatments for neuronal excitability disorders such as depression, epilepsy and anxiety.
The startup’s lead drug candidates are ETX-810, a potential treatment for chronic pain, and ETX-155, which is being developed to treat major depressive disorder, perimenopausal depression and focal onset seizures.
Eliem plans…
